![]() ![]() Existing medications for social anxiety are slow to work or are fraught with adverse effects. Reid Robison, Chief Medical Officer and Principal Investigator, commented: "Social Anxiety Disorder is an understudied mental health condition and yet it's very common with widespread impact across multiple domains of life. Current medical interventions include SSRIs, beta-blockers and anti-anxiety medications such as benzodiazepines.ĭr. People with SAD experience extreme fear in social situations, when meeting new people or speaking in front of others, which can severely and negatively impact relationships, work and daily life. The PREVAIL Trial will examine the safety and efficacy of Bionomics' propriety drug candidate, BNC210, versus a placebo in reducing self-reported anxiety severity when participants take part in an anxiety-provoking behavioral task involving a speaking challenge. 1 The phase II randomized clinical study for the acute treatment of SAD (the "PREVAIL Trial") is sponsored by Bionomics Limited, a clinical-stage biopharmaceutical company ("Bionomics") (NASDAQ:BNOX) (ASX:BNO) and is currently enrolling patients at Novamind's Draper, Utah, research site. ![]() The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.TORONTO, ON / ACCESSWIRE / / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for the acute treatment of social anxiety disorder (SAD), an understudied and common mental health condition that affects nearly 15 million American adults. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. ![]() The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. Novamind stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Novamind. For every potential investor in Novamind, whether a beginner or expert, Novamind's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. The Company enables access to psychedelic medicine through a network of clinics, retreats and clinical research sites. Novamind Inc., formerly Hinterland Metals Inc., is a Canada-based mental health company. Support for the NovaMind iOS and Android apps will be suspended immediately, and NovaMind Cloud will be shut. In a statement on the NovaMind home page, Klug says he plans to continue development of the Mac and PC versions of the program. The new owner, Patrick Klug, is a former NovaMind developer who worked extensively on the NovaMind 5 release. ![]()
0 Comments
Leave a Reply. |